Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• BRAF serine/threonine kinase gene mutations are common in cutaneous melanomas.
• Hypoxia-inducible factor-1alpha (HIF-1alpha) activation is crucial in cancer development and progression, responding to hypoxic stress and oncogenic signals.

Purpose of the Study:

• To investigate the relationship between BRAF(V600E) mutation and HIF-1alpha expression in melanoma cells.
• To determine the role of BRAF and HIF-1alpha in melanoma cell survival and proliferation under hypoxic conditions.

Main Methods:

• Microarray profiling of 35 melanoma and melanocyte cell lines.
• RNA interference to suppress BRAF (V600E) and wild-type BRAF.
• Cell survival and proliferation assays under hypoxic conditions.
• Rescue experiments by reintroducing BRAF(V600E).
• Pharmacologic inhibition of BRAF using BAY 43-9006.

Main Results:

• HIF-1alpha gene expression was significantly increased in melanomas with BRAF(V600E) mutation.
• Suppression of BRAF(V600E) led to decreased HIF-1alpha expression and reduced cell survival/proliferation under hypoxia.
• Knockdown of HIF-1alpha decreased melanoma cell survival under hypoxia.
• Pharmacologic BRAF inhibition decreased HIF-1alpha expression.
• BRAF knockdown increased von Hippel-Lindau protein expression, correlating with decreased HIF-1alpha stability.

Conclusions:

• BRAF(V600E) mutation increases HIF-1alpha expression and promotes melanoma cell survival under hypoxic conditions.
• The oncogenic effects of BRAF(V600E) may be partly mediated through the HIF-1alpha pathway.
• Targeting BRAF or HIF-1alpha could be potential therapeutic strategies for melanoma.